GRI Bio (GRI) Stock Price, News & Analysis

Company Overview

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Key Stats

• Today's Range: $1.90 to $2.67
• 50-Day Range: $1.38 to $2.88
• 52-Week Range: $1.36 to $80.36
• Volume: 717,878 shs
• Average Volume: 279,520 shs
• Market Capitalization: $4.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Hold

GRI Bio Stock Analysis - MarketRank™

GRI Bio scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

GRI Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

GRI Bio has a consensus price target of $32.00, representing about 1,512.1% upside from its current price of $1.99.

Amount of Analyst Coverage

GRI Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GRI Bio are expected to grow in the coming year, from ($4.27) to ($2.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GRI Bio is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GRI Bio is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GRI Bio has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.37% of the float of GRI Bio has been sold short.

Short Interest Ratio / Days to Cover

GRI Bio has a short interest ratio ("days to cover") of 0.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GRI Bio has recently increased by 15.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GRI Bio does not currently pay a dividend.

Dividend Growth

GRI Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for GRI Bio this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for GRI on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

1 people have added GRI Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GRI Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.73% of the stock of GRI Bio is held by insiders.

Percentage Held by Institutions

33.95% of the stock of GRI Bio is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/08/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:GRI
• Previous Symbol: NASDAQ:VLON
• CIK: 1824293
• Web: www.vallon-pharma.com
• Phone: 267-607-8255
• Fax: N/A
• Employees: 1
• Year Founded: 2009

Price Target and Rating

• Average Price Target for GRI Bio: $32.00
• High Price Target: $32.00
• Low Price Target: $32.00
• Potential Upside/Downside: +1,500.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($38.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -134.03%
• Return on Assets: -106.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.30
• Quick Ratio: 10.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.16 per share
• Price / Book: 0.48

Miscellaneous

• Outstanding Shares: 2,190,000
• Free Float: 1,995,000
• Market Cap: $4.38 million
• Optionable: Not Optionable
• Beta: -1.24